OPGEN, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.57 USD | -2.65% |
|
+1.10% | -38.81% |
| 06-03 | OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 05-30 | OpGen, Inc. Announces Appointments to the Committees of the Board | CI |
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, welcome to the OpGen Sec...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -38.81% | 3.33M | |
| +48.75% | 57.87B | |
| +41.65% | 40.25B | |
| -7.34% | 39.94B | |
| -5.96% | 28.54B | |
| +12.43% | 26.4B | |
| -20.12% | 19.33B | |
| +30.27% | 12.4B | |
| -0.69% | 12.23B | |
| +24.79% | 12.2B |
- Stock Market
- Equities
- OPGN Stock
- News OpGen, Inc.
- Transcript : OpGen, Inc., Q2 2022 Earnings Call, Aug 11, 2022
